TYP — Tryptamine Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$51.80m
- AU$48.77m
- AU$1.59m
- 35
- 14
- 63
- 30
Annual income statement for Tryptamine Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 10 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.2 | 4.21 | 3.41 | 1.12 | 1.59 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.7 | 14.3 | 10.5 | 6.72 | 6.87 |
| Operating Profit | -8.47 | -10.1 | -7.13 | -5.6 | -5.28 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.47 | -10.1 | -7.13 | -6.14 | -5.33 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.47 | -10.1 | -7.13 | -6.14 | -5.33 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.47 | -10.1 | -7.13 | -6.14 | -5.33 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.47 | -10.1 | -7.13 | -6.14 | -5.33 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.057 | -0.057 | -0.036 | -0.009 | -0.004 |
| Dividends per Share |